Tagged with

Ukraine Vladimir Tkachenko, general manager of AMAXA PHARMA, a UK-headquartered pharmaceutical company focused on life-threatening therapeutic areas such as oncology and neonatology in the CIS countries, provides insights into AMAXA’s market positioning in Ukraine and the region, as well as his strategic priorities to further propel the eye-catching development pace of…

Hong Kong Henry Yau, MD and Honorary Assistant Professor at the University of Hong Kong Clinical Trials Centre (HKU-CTC) discusses the center’s development, the diverse range of services it offers, and the clinical trials environment in Hong Kong. Having been with the organization since nearly the beginning from 2000, how have you…

Austria Dr. Wolfgang Andiel, president of the Austrian Association of Generic Medicines (OeGV, Österreichischer Generikaverband), which acts as a unified voice to represent generics companies in Austria, provides an in-depth analysis of the vicious cycle associated with establishing generics market share in Austria as well as the inconsistences of government regulations…

Ukraine Mykola Gumenyuk, CEO of Yuria-Pharm, documents the strategy that has been driving the impressive growth of this ambitious company, how Yuria-Pharm has evolved into the leading manufacturer of solutions for infusions and hospital supplier in Ukraine and CIS, and how it plans to significantly increase its international activities in all…

USA Speaking exclusively to PharmaBoardroom at the 2017 BIO Convention in San Diego, former FDA Commissioner Andrew von Eschenbach lifts the lid on the ‘FDA Beyond Our Borders’ project that he initiated. Dr. von Eschenbach, you were the FDA Commissioner for three years, from 2006 to 2009. What do you see…

Indonesia Darodjatun Sanusi, Executive Director of GP Farmasi (National Association of Local Companies in Indonesia), explains the opportunities and challenges that his members are facing as well as the future directions that the industry should take to further enhance its capabilities and continue its growth. As Executive Director of GP Farmasi,…

Hong Kong Shawn, as I understand, SinoMab today is a clinical stage biopharma company focusing on the development of therapeutic monoclonal antibodies (mAbs) – hence the name. Can you tell us a little about the genesis of the company? Having previously studied and worked in the UK and US, I was asked…

Hong Kong Andy Barnett, general manager (Hong Kong and Macau) for Roche, discusses the highlights of his past two years managing a local affiliate instead of heading a global business line, the key factors behind Roche’s top-5 positioning in the local market, and the huge potential for innovation in aspects like digital…

Mexico According to a recent World Health Organization study, countries must allocate at least six percent of their GDP to research and development to be considered to have a healthy investment in this area. As Mexico currently only invests 1.8 percent of its GDP into R&D, there is clearly still a…

Indonesia Rufi Susanto, President (Core Market) and Senior Managing Director IDS Medical Systems (idsMED), highlights the company’s commitment to Indonesia and believes that idsMED’s employees, in combination with continuous investment in their education, are key to making the company succeed. Mr. Susanto, you hold two management roles within idsMED, being the…

Hong Kong Lawrence Wong, general manager of Ferring Pharmaceuticals in Hong Kong, discusses the important role of the Hong Kong affiliate in support of regional operations, the value of the Hong Kong market given that Ferring offers most of its global portfolio here, and how the company philosophy ‘People come first at…

Indonesia Steven Lee, country lead at Siemens Healthineers Indonesia, expands on the strategic change that the company is undergoing in order to fully capture the potential of the Indonesian public and private market. In 2015, Siemens made its healthcare unit an independent organization and just a year ago changed its name…